World's Best Scientists 2026 revealed!

D-Index & Metrics

Biology and Biochemistry

D-Index
66
Citations
31188
World Ranking
8442
National Ranking
222

Daniel S. Peeper publication distribution in Biology and Biochemistry in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Biology and Biochemistry in 2026. The highlighted bar marks where Daniel S. Peeper sits on this spectrum.

47–56 publications: 8 scientists 57–66 publications: 35 scientists 67–76 publications: 106 scientists 77–86 publications: 231 scientists 87–96 publications: 414 scientists 97–106 publications: 546 scientists 107–116 publications: 704 scientists 117–126 publications: 849 scientists 127–136 publications: 980 scientists 137–146 publications: 942 scientists 147–156 publications: 969 scientists 157–166 publications: 950 scientists 167–176 publications: 951 scientists 177–186 publications: 915 scientists 187–196 publications: 787 scientists 197–206 publications: 841 scientists 207–216 publications: 735 scientists 217–226 publications: 709 scientists 227–236 publications: 651 scientists 237–246 publications: 605 scientists 247–256 publications: 510 scientists 257–266 publications: 524 scientists 267–276 publications: 434 scientists 277–286 publications: 418 scientists 287–296 publications: 350 scientists 297–306 publications: 363 scientists 307–316 publications: 315 scientists 317–326 publications: 296 scientists 327–336 publications: 261 scientists 337–346 publications: 240 scientists 347–356 publications: 219 scientists 357–366 publications: 197 scientists 367–376 publications: 154 scientists 377–386 publications: 161 scientists 387–396 publications: 155 scientists 397–406 publications: 145 scientists 407–416 publications: 124 scientists 417–426 publications: 112 scientists 427–436 publications: 132 scientists 437–446 publications: 116 scientists 447–456 publications: 99 scientists 457–466 publications: 81 scientists 467–476 publications: 91 scientists 477–486 publications: 80 scientists 487–496 publications: 80 scientists 497–506 publications: 60 scientists 507–516 publications: 36 scientists 517–526 publications: 46 scientists 527–536 publications: 54 scientists 537–546 publications: 44 scientists 547–556 publications: 43 scientists 557–566 publications: 43 scientists 567–576 publications: 42 scientists 577–586 publications: 25 scientists 587–596 publications: 34 scientists 597–606 publications: 23 scientists 607–616 publications: 33 scientists 617–626 publications: 31 scientists 627–636 publications: 27 scientists 637–646 publications: 25 scientists 647–656 publications: 28 scientists 657–666 publications: 34 scientists 667–676 publications: 18 scientists 677–686 publications: 16 scientists 687–696 publications: 10 scientists 697–706 publications: 12 scientists 707–716 publications: 21 scientists 717–726 publications: 12 scientists 727–736 publications: 12 scientists 737–746 publications: 10 scientists 747–756 publications: 7 scientists 757–766 publications: 13 scientists 767–776 publications: 15 scientists 777–786 publications: 13 scientists 787–796 publications: 9 scientists 797–806 publications: 9 scientists 807–816 publications: 7 scientists 817–826 publications: 4 scientists 827–836 publications: 9 scientists 837–846 publications: 7 scientists 847–856 publications: 3 scientists 857–866 publications: 5 scientists 867–876 publications: 5 scientists 877–886 publications: 11 scientists 887–896 publications: 3 scientists 897–906 publications: 4 scientists 907–916 publications: 7 scientists 917–926 publications: 5 scientists 927–936 publications: 6 scientists 937–946 publications: 6 scientists 947–956 publications: 3 scientists 957–966 publications: 7 scientists 967–976 publications: 2 scientists 977–986 publications: 2 scientists 987–996 publications: 1 scientists 997–1,006 publications: 5 scientists 1,007–1,016 publications: 2 scientists 1,017–1,026 publications: 2 scientists 1,027 publications: 1 scientists 1,028+ publications: 100 scientists
47 publications 1,028+

This scientist: 189 publications — 45th percentile

45% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,028 publications or more.

Daniel S. Peeper D-index placement in Biology and Biochemistry in 2026

The chart shows the D-index (discipline H-index) distribution of Biology and Biochemistry scientists ranked by Research.com in 2026. The highlighted bar marks where Daniel S. Peeper sits on this spectrum.

40–41 D-Index: 80 scientists 42–43 D-Index: 183 scientists 44–45 D-Index: 317 scientists 46–47 D-Index: 504 scientists 48–49 D-Index: 718 scientists 50–51 D-Index: 900 scientists 52–53 D-Index: 1,026 scientists 54–55 D-Index: 1,150 scientists 56–57 D-Index: 1,236 scientists 58–59 D-Index: 1,253 scientists 60–61 D-Index: 1,163 scientists 62–63 D-Index: 1,131 scientists 64–65 D-Index: 1,032 scientists 66–67 D-Index: 897 scientists 68–69 D-Index: 814 scientists 70–71 D-Index: 715 scientists 72–73 D-Index: 709 scientists 74–75 D-Index: 596 scientists 76–77 D-Index: 512 scientists 78–79 D-Index: 473 scientists 80–81 D-Index: 412 scientists 82–83 D-Index: 373 scientists 84–85 D-Index: 358 scientists 86–87 D-Index: 285 scientists 88–89 D-Index: 273 scientists 90–91 D-Index: 227 scientists 92–93 D-Index: 208 scientists 94–95 D-Index: 193 scientists 96–97 D-Index: 153 scientists 98–99 D-Index: 157 scientists 100–101 D-Index: 148 scientists 102–103 D-Index: 120 scientists 104–105 D-Index: 113 scientists 106–107 D-Index: 100 scientists 108–109 D-Index: 86 scientists 110–111 D-Index: 67 scientists 112–113 D-Index: 72 scientists 114–115 D-Index: 73 scientists 116–117 D-Index: 64 scientists 118–119 D-Index: 53 scientists 120–121 D-Index: 60 scientists 122–123 D-Index: 54 scientists 124–125 D-Index: 43 scientists 126–127 D-Index: 38 scientists 128–129 D-Index: 49 scientists 130–131 D-Index: 26 scientists 132–133 D-Index: 18 scientists 134–135 D-Index: 23 scientists 136–137 D-Index: 32 scientists 138–139 D-Index: 32 scientists 140–141 D-Index: 27 scientists 142–143 D-Index: 19 scientists 144–145 D-Index: 22 scientists 146–147 D-Index: 12 scientists 148–149 D-Index: 16 scientists 150–151 D-Index: 14 scientists 152–153 D-Index: 10 scientists 154–155 D-Index: 13 scientists 156–157 D-Index: 10 scientists 158–159 D-Index: 7 scientists 160–161 D-Index: 9 scientists 162–163 D-Index: 13 scientists 164–165 D-Index: 4 scientists 166 D-Index: 4 scientists 167+ D-Index: 98 scientists
40 D-Index 167+

This scientist: 66 D-Index — 57th percentile

57% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 167 D-Index or more.

Research.com Recognitions

  • 2016 - Member of Academia Europaea
  • Member of the European Molecular Biology Organization (EMBO)
  • Member of the European Molecular Biology Organization (EMBO)
  • Member of the European Molecular Biology Organization (EMBO)

Overview

Daniel S. Peeper is affiliated with the Antoni van Leeuwenhoek Hospital in the Netherlands and has a research focus that spans medicine, biochemistry, genetics, molecular biology, immunology, and microbiology. Their work concentrates heavily on oncology, molecular biology, immunology, cancer research, and pulmonary and respiratory medicine. This multidisciplinary approach is reflected in numerous publications and collaborations.

The scientist's research covers key topics such as cancer immunotherapy and biomarkers, CAR-T cell therapy research, immunotherapy and immune responses, immune cell function and interaction, immune cells in cancer, RNA modifications and cancer, and melanoma and MAPK pathways.

Their publication record includes articles in high-impact journals such as Nature, Nature Communications, Nature Medicine, Science, Molecular Cell, and bioRxiv. Some of the notable recent papers authored or co-authored by Daniel S. Peeper include:

  • B cells and tertiary lymphoid structures promote immunotherapy response (2020, Nature)
  • The human tumor microbiome is composed of tumor type-specific intracellular bacteria (2020, Science)
  • Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma (2021, Nature Medicine)
  • Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma (2021, Nature Communications)
  • Rational Cancer Treatment Combinations: An Urgent Clinical Need (2020, Molecular Cell)

Daniel S. Peeper collaborates frequently with a group of co-authors that includes Oscar Krijgsman, David W. Vredevoogd, Maarten Altelaar, Christian U. Blank, and Maarten A. Ligtenberg. These partnerships have contributed to a range of publications that reinforce their research presence across various subfields and topics.

Frequent publication venues where their work appears include bioRxiv (Cold Spring Harbor Laboratory), Nature, Nature Communications, Journal for ImmunoTherapy of Cancer, and Cancer Research, indicating a consistent output in both preprint and peer-reviewed literature.

Throughout their career, Daniel S. Peeper has been involved extensively in oncology-related research, with a special emphasis on cancer immunotherapy and biomarkers. Their work often intersects molecular biology and immunology aspects pertinent to cancer progression and therapy.

Awards recognizing their contributions include membership in the Academia Europaea since 2016 and membership in the European Molecular Biology Organization (EMBO).

Best Publications

  • BRAFE600-associated senescence-like cell cycle arrest of human naevi

    Chrysiis Michaloglou;Liesbeth C. W. Vredeveld;Maria S. Soengas;Christophe Denoyelle

  • B cells and tertiary lymphoid structures promote immunotherapy response

    Beth A. Helmink;Sangeetha M. Reddy;Jianjun Gao;Shaojun Zhang

  • The essence of senescence

    Thomas Kuilman;Chrysiis Michaloglou;Wolter J. Mooi;Daniel S. Peeper

  • Oncogene-Induced Senescence Relayed by an Interleukin-Dependent Inflammatory Network

    Thomas Kuilman;Chrysiis Michaloglou;Liesbeth C.W. Vredeveld;Sirith Douma

  • The human tumor microbiome is composed of tumor type–specific intracellular bacteria

    Deborah Nejman;Ilana Livyatan;Garold Fuks;Nancy Gavert

  • Senescence-messaging secretome: SMS-ing cellular stress

    Thomas Kuilman;Daniel S. Peeper

  • Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB

    Sirith Douma;Theo van Laar;John Zevenhoven;Ralph Meuwissen

  • The KLF4 tumour suppressor is a transcriptional repressor of p53 that acts as a context-dependent oncogene

    Benjamin D. Rowland;René Bernards;Daniel S. Peeper

  • Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma

    Christian U. Blank;Elisa A. Rozeman;Lorenzo F. Fanchi;Karolina Sikorska

  • A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence

    Joanna Kaplon;Liang Zheng;Katrin Meissl;Barbara Chaneton

  • KLF4, p21 and context-dependent opposing forces in cancer.

    Benjamin D. Rowland;Daniel S. Peeper

  • Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma.

    Judith Müller;Oscar Krijgsman;Jennifer Tsoi;Lidia Robert

  • Interrogating open issues in cancer precision medicine with patient-derived xenografts

    Annette T. Byrne;Denis G. Alférez;Frédéric Amant;Daniela Annibali

  • Cell cycle-specific association of E2F with the p130 E1A-binding protein.

    D Cobrinik;P Whyte;D S Peeper;T Jacks

  • Ras signalling linked to the cell-cycle machinery by the retinoblastoma protein

    Daniel S. Peeper;Daniel S. Peeper;Todd M. Upton;Mohamed H. Ladha;Elizabeth Neuman

  • Oncogene-induced cell senescence--halting on the road to cancer.

    W J Mooi;D S Peeper

  • Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial.

    Elisa A Rozeman;Alexander M Menzies;Alexander C J van Akkooi;Chandra Adhikari

  • Preserved genetic diversity in organoids cultured from biopsies of human colorectal cancer metastases

    Fleur Weeber;Marc van de Wetering;Marlous Hoogstraat;Krijn K Dijkstra

  • The kinesin KIF1Bβ acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor

    Susanne Schlisio;Rajappa S. Kenchappa;Liesbeth C.W. Vredeveld;Rani E. George

  • Cellular senescence in vivo: a barrier to tumorigenesis.

    Alexandre Prieur;Daniel S Peeper

Frequent Co-Authors

Christian U. Blank
Christian U. Blank Antoni van Leeuwenhoek Hospital
Lodewyk F. A. Wessels
Lodewyk F. A. Wessels Antoni van Leeuwenhoek Hospital
Ton N. M. Schumacher
Ton N. M. Schumacher Antoni van Leeuwenhoek Hospital
David J. Adams
David J. Adams Wellcome Sanger Institute
René Bernards
René Bernards Antoni van Leeuwenhoek Hospital
Ultan McDermott
Ultan McDermott AstraZeneca (United Kingdom)
John B. A. G. Haanen
John B. A. G. Haanen Antoni van Leeuwenhoek Hospital
Emile E. Voest
Emile E. Voest Antoni van Leeuwenhoek Hospital
Jos Jonkers
Jos Jonkers Antoni van Leeuwenhoek Hospital
Annegien Broeks
Annegien Broeks Antoni van Leeuwenhoek Hospital

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re considering advancing your education in Biology, Biochemistry, or related fields, there are a variety of online degree and certification options to help accelerate your career. Students interested in health and nutrition can explore fast track nutrition degree online programs. These allow you to earn credentials quickly and efficiently, opening opportunities in dietetics, health education, or wellness coaching.

For those who wish to combine scientific training with business skills, an MBA in Healthcare Management may be a strong choice. Investigate the healthcare mba cost to find programs that fit both your budget and career ambitions, particularly if you’re aiming for leadership roles in the medical or biotechnological sectors.

Healthcare administration also offers certification pathways. If you are interested in medical coding, understanding the cpc vs ccs certification differences is crucial for choosing the right credential. Each certification prepares you for specific roles and salary prospects in medical billing and records management. For more information about earnings potential, see current medical.coder salary data to guide your career planning.

Best Scientists Citing Daniel S. Peeper

Trending Scientists

Recently Published Articles